Close

Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan

Go back to Alnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan

Alnylam Pharmaceuticals Discontinues Revusiran Development

October 5, 2016 4:30 PM EDT

Decision Does Not Impact Patisiran or Any Other RNAi Therapeutic Program in Development

Company to Host Conference Call Today at 5:00 p.m. ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend... More